Home > Insider Trading > Filing (0000950103-23-007785)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1802768	Royalty Pharma Plc	RPRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1507678	G. Pablo Legorreta	C/O Royalty Pharma Plc 110 E. 59Th Street New York NY 10022	Ceo, Chairman Of The Board	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Ordinary Shares	Acquisiton	2023-05-24	150,000	$32.25	380,000	No	4	P	Indirect	By Legorreta 2023 SR Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Legorreta 2023 SR Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Ordinary Shares	63,795	Direct
Class A Ordinary Shares	460,139	Indirect	By Legorreta Investments LLC
Class A Ordinary Shares	1,284,590	Indirect	By GST-Exempt Legorreta 2012 Family Trust
Class A Ordinary Shares	41,306	Indirect	By GST-Exempt Legorreta 2020 Family Trust
Class A Ordinary Shares	10,000	Indirect	By Child
Class A Ordinary Shares	10,000	Indirect	By Child
Class A Ordinary Shares	123,310	Indirect	By IRRA
Class A Ordinary Shares	118,500	Indirect	By SEP/IRA
Class A Ordinary Shares	1,040,410	Indirect	By Legorreta Children 2002 Trust
Class A Ordinary Shares	6,930	Indirect	By Spouse

Footnotes

Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.
The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.20 to $32.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.